Skip to main content
TipRanks
Go Ultimate75% OFF

Actuate Therapeutics, Inc. (ACTU) Stock Statistics & Valuation Metrics

57 Followers

Total Valuation

Actuate Therapeutics, Inc. has a market cap or net worth of $16.18M. The enterprise value is $41.32T.

Market Cap
$16.18M
Enterprise Value
$41.32T

Share Statistics

Actuate Therapeutics, Inc. has 60,382,824 shares outstanding. The number of shares has decreased by -2.65% in one year.

Shares Outstanding
60,382,824
Owned by Insiders
24.77%
Owned by Institutions
24.41%

Financial Efficiency

Actuate Therapeutics, Inc.’s return on equity (ROE) is -2.81 and return on invested capital (ROIC) is -270.08%.

Return on Equity (ROE)
-2.81
Return on Assets (ROA)
-1.58
Return on Invested Capital (ROIC)
-270.08%
Return on Capital Employed (ROCE)
-2.70
Revenue Per Employee
0
Profits Per Employee
-1.85M
Employee Count
12
Asset Turnover
0.00
Inventory Turnover
0.00

Valuation Ratios

The current PE Ratio of Actuate Therapeutics, Inc. is -0.35. Actuate Therapeutics, Inc.’s PEG ratio is -0.01.

PE Ratio
-0.35
PS Ratio
0.00
PB Ratio
-8.19
Price to FCF
-0.41
Price to Operating Cash Flow
-0.41
PEG Ratio
-0.01

Income Statement

In the last 12 months, Actuate Therapeutics, Inc. had revenue of 0 and earned -22.23M in profits. Earnings per share was -1.06.

Revenue
0
Gross Profit
0
Operating Income
-22.50M
Pretax Income
-22.23M
Net Income
-22.23M
EBITDA
-22.21M
Earnings Per Share (EPS)
-1.06

Cash Flow

In the last 12 months, operating cash flow was -16.11M and capital expenditures -4, giving a free cash flow of -16.11M billion.

Operating Cash Flow
-16.11M
Free Cash Flow
-16.11M
Free Cash Flow per Share
-0.67

Dividends & Yields

Actuate Therapeutics, Inc. pays an annual dividend of ―, resulting in a dividend yield of ―

Dividend Per Share
―
Dividend Yield
―
Payout Ratio
N/A
Free Cash Flow Yield
-242.17%
Earnings Yield
-275.23%

Stock Price Statistics

Beta
1.31
52-Week Price Change
-95.47%
50-Day Moving Average
0.67
200-Day Moving Average
1.86
Relative Strength Index (RSI)
28.75
Average Volume (3m)
427.40K

Financial Position

Actuate Therapeutics, Inc. as a current ratio of 2.39, with Debt / Equity ratio of 5.11%

Current Ratio
2.39
Quick Ratio
2.39
Debt to Market Cap
0.00
Net Debt to EBITDA
0.57
Interest Coverage Ratio
-1110.88

Taxes

In the past 12 months, Actuate Therapeutics, Inc. has paid 0 in taxes.

Income Tax
0
Effective Tax Rate
0.00

Enterprise Valuation

Actuate Therapeutics, Inc. EV to EBITDA ratio is -0.27, with an EV/FCF ratio of -0.31.

EV to Sales
0.00
EV to EBITDA
-0.27
EV to Free Cash Flow
-0.31
EV to Operating Cash Flow
-0.31

Balance Sheet

Actuate Therapeutics, Inc. has $2.10M in cash and marketable securities with $404.99K in debt, giving a net cash position of $1.70M billion.

Cash & Marketable Securities
$2.10M
Total Debt
$404.99K
Net Cash
$1.70M
Net Cash Per Share
$0.03
Tangible Book Value Per Share
-$0.03

Margins

Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.

Gross Margin
0.00%
Operating Margin
0.00%
Pretax Margin
0.00%
Net Profit Margin
0.00%
EBITDA Margin
0.00%
EBIT Margin
0.00%

Analyst Forecast

The average price target for Actuate Therapeutics, Inc. is $10.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy

Price Target
$10.00
Price Target Upside
3631.34% Upside
Analyst Consensus
Moderate Buy
Analyst Count
1
Revenue Growth Forecast
―
EPS Growth Forecast
35.52%